Moreover, in vitro experiments showed that CD1d ligation can cooperate with other anti-myeloma agents to induce cell death (Spanoudakis et al., 2009), raising the possibility of incorporating αCD1d antibody treatment to the arsenal of therapies targeting early-stage myeloma. The gene discussed is CD1D; the disease is plasma cell myeloma.